Abstract
Orthopedic surgery in patients with hemophilia should be planned by the surgeon together with the hemophilia specialist and the physiotherapist, in order to establish a long-term program that integrates surgery with medical and rehabilitative interventions. Orthopedic surgery should be performed in centres that are able to provide hematologic expertise, medical support, and laboratory monitoring of coagulation throughout the period of hospitalization.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A (1977) 1-Deamino-8-D-Arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand’s disease. Lancet i:869–872
Santagostino E, Mannucci PM (2000) Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 6:1–10
United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) (2003) Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 9:1–23
Fletcher ML, Trowell JM, Craske J et al (1983) Non-A, non-B hepatitis after transfusion of factor VIII in unfrequently treated patients. Br Med J 287:1754–1757
Kernoff PBA, Lee CA, Karayanis P, Thomas HC (1985) High risk of non-A, non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol 60:469–479
Powell DL, Whitener CJ, Dye CE et al (2005) Knee and hip arthroplasty infection rates in persons with haemophilia: a 27 year single center experience during the HIV epidemic. Haemophilia 11:233–239
Wilde JT, Lee CA, Collins P et al (1999) Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders. Br J Haematol 107: 556–569
Martinowitz U, Schulman S, Gitel S et al (1992) Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 82:729–734
Schulman S, Gitel S, Martinowitz U (1994) Stability of factor VIII concentrates after reconstitution. Am J Hematol 45:217–223
Schulman S, Varon D, Keller N et al (1994) Monoclonal purified FVIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemost 72:403–407
Chowdary P, Dasani H, Jones JA et al (2001) Recombinant factor IX (BeneFix) by adjusted continuous infusion: a study of stability, sterility and clinical experience. Haemophilia 7:140–145
Sharathkumar A, Lillicrap D, Blanchette VS et al (2003) Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 1:1228–1236
White B, Cotter M, Byrne M et al (2000) High responding factor VIII inhibitors in mild haemophilia — is there a link with recent changes in clinical practice? Haemophilia 6:113–115
Rickard KA (1995) Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemophilia 1(Suppl 1):8–13
Dingli D, Gastineau DA, Gilchrist GS et al (2002) Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates. Haemophilia 8:629–634
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer
About this chapter
Cite this chapter
Mancuso, M.E., Santagostino, E. (2008). Peri-operative and Post-operative Management of Hemophiliac Patients without Inhibitors. In: Caviglia, H.A., Solimeno, L.P. (eds) Orthopedic Surgery in Patients with Hemophilia. Springer, Milano. https://doi.org/10.1007/978-88-470-0854-0_6
Download citation
DOI: https://doi.org/10.1007/978-88-470-0854-0_6
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0853-3
Online ISBN: 978-88-470-0854-0
eBook Packages: MedicineMedicine (R0)